---
title: "Fresh2 (FRES.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/FRES.US.md"
symbol: "FRES.US"
name: "Fresh2"
industry: "生物技术"
---

# Fresh2 (FRES.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |

## Company Profile

Fresh2 Group Limited，一家生物技术公司，致力于利用癌变分化分析技术和设备，为中国的企业和人寿保险公司提供多种癌症筛查和检测测试，并进行研究、开发、市场推广和销售。同时，公司还提供体检套餐以及市场研究、设计、编码、开发、测试等技术服务。此外，该公司还销售基因检测套装和护肤产品，并拥有核心技术平台，从事技术开发和产品分销。此外，它还运营一个电子商务平台，连接食品供应商、超市经营者和餐厅业主。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:15.000Z

**Overall: C (0.53)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Median | D |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 78.46% |  |
| Net Profit YoY | -4.17% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 2.40M |  |


**Multi Score**: C

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -264.77% | E |
| Profit Margin | -733.70% | E |
| Gross Margin | 0.00% | E |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 78.46% | A |
| Net Profit YoY | -4.17% | C |
| Total Assets YoY | 169.43% | A |
| Net Assets YoY | 564.20% | A |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -13.63% | D |
| OCF YoY | 78.46% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.14 | D |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 37.12% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Fresh2",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-264.77%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-733.70%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "78.46%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-4.17%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "169.43%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "564.20%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-13.63%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "78.46%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.14",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "37.12%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.85 |
| Highest Target | 1600.00 |
| Lowest Target | 1600.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/FRES.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/FRES.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/FRES.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.